mesothelioma treatment market is expected to grow at a CAGR of 8.7% during CAGR 2021 to 2027. Mesothelioma is a rare and aggressive form of cancer that occurs in the thin layer tissue that covers the majority of the internal organs. Mesothelioma most often affects the tissue that surrounds the lungs (pleura), which is called pleural mesothelioma. Other, rarer types of mesothelioma affect tissue in the abdomen (peritoneal mesothelioma), around the heart and around the testicles. Pleural mesothelioma is the most common type of mesothelioma. Mesothelioma primarily caused by the inhalation of asbestos fibers, can be diagnosed in older individuals who worked with asbestos products in an industrial setting as there is no cure currently exists, mesothelioma patients can usually improve their prognosis through some form of treatment available. Chemotherapy is a crucial component of palliative care. AstraZeneca, for example, is active in the research and development of medicines for malignant mesothelioma. Durvalumab, tazemetostat, tremelimumab, nintedanib, ADI-PEG 20, and HSV 1716 are all major pipeline medicines. Because of the rising incidence rate, rising air pollution, rising senior population, and rising healthcare cost, the malignant mesothelioma market is expected to see significant expansion in the near future. Moreover, throughout the projected period, the development of novel therapies and the introduction of advanced treatment options are expected to present attractive potential prospects for the malignant mesothelioma market. However, the mesothelioma market is constrained by a long latent period between development and symptom, a lack of effective treatment, and a low surveillance rate.